share_log

Xenon Pharmaceuticals Analyst Ratings

Benzinga Analyst Ratings ·  Jan 31, 2023 07:43
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/31/2023 34.21% RBC Capital $49 → $51 Maintains Outperform
12/14/2022 57.89% Goldman Sachs → $60 Initiates Coverage On → Buy
12/12/2022 Cowen & Co. Initiates Coverage On → Outperform
11/28/2022 31.58% Wells Fargo → $50 Initiates Coverage On → Overweight
11/11/2022 28.95% Guggenheim $53 → $49 Maintains Buy
10/19/2022 36.84% Raymond James → $52 Initiates Coverage On → Outperform
10/11/2022 28.95% RBC Capital $46 → $49 Maintains Outperform
08/29/2022 B of A Securities Initiates Coverage On → Buy
08/11/2022 21.05% SVB Leerink $40 → $46 Maintains Outperform
08/10/2022 21.05% RBC Capital $41 → $46 Maintains Outperform
07/21/2022 44.74% JP Morgan → $55 Initiates Coverage On → Overweight
06/27/2022 7.89% Wedbush $47 → $41 Maintains Outperform
05/11/2022 7.89% RBC Capital $43 → $41 Maintains Outperform
11/11/2021 5.26% SVB Leerink $34 → $40 Maintains Outperform
10/28/2021 13.16% RBC Capital → $43 Initiates Coverage On → Outperform
10/04/2021 26.32% Needham $25 → $48 Maintains Buy
03/02/2021 -34.21% Needham $22 → $25 Maintains Buy
03/02/2021 -26.32% SVB Leerink $25 → $28 Maintains Outperform
10/02/2020 -42.11% SVB Leerink → $22 Initiates Coverage On → Outperform
07/21/2020 -42.11% Needham → $22 Initiates Coverage On → Buy
06/01/2020 -39.47% Jefferies $16 → $23 Assumes → Buy
03/25/2020 -39.47% Wedbush → $23 Initiates Coverage On → Outperform
01/08/2020 William Blair Initiates Coverage On → Outperform
09/20/2019 -34.21% Guggenheim → $25 Initiates Coverage On → Buy
03/29/2019 Stifel Assumes → Buy
08/08/2018 -60.53% Stifel $9 → $15 Maintains Buy
03/08/2018 -76.32% Stifel $7 → $9 Maintains Buy

What is the target price for Xenon Pharmaceuticals (XENE)?

The latest price target for Xenon Pharmaceuticals (NASDAQ: XENE) was reported by RBC Capital on January 31, 2023. The analyst firm set a price target for $51.00 expecting XENE to rise to within 12 months (a possible 34.21% upside). 13 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Xenon Pharmaceuticals (XENE)?

The latest analyst rating for Xenon Pharmaceuticals (NASDAQ: XENE) was provided by RBC Capital, and Xenon Pharmaceuticals maintained their outperform rating.

When is the next analyst rating going to be posted or updated for Xenon Pharmaceuticals (XENE)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.

Is the Analyst Rating Xenon Pharmaceuticals (XENE) correct?

While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a maintained with a price target of $49.00 to $51.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $38.00, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment